Artivion (AORT) AI Stock Analysis

• Market Cap: $1.34B
• Dividend Yield: N/A
• Average Volume (3M): 318.09K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.97
• Revenue Growth: 5.94%
• EPS Growth: -115.82%
• Country: US
• Employees: 1,600
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Devices
• EPS (TTM): -0.01
• Shares Outstanding: 42,702,785
• 10 Day Avg. Volume: 253,267
• 30 Day Avg. Volume: 318,086
• PEG Ratio: 1.04
• Price to Book (P/B): 4.50
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 633.37
• Enterprise Value/Market Cap: 1.24
• Enterprise Value/Revenue: 1.08
• Enterprise Value/Gross Profit: 6.64
• Enterprise Value/Ebitda: 8.63
• 1Y Price Target: $33.00
• Price Target Upside: 4.76% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 68 Neutral
• Price Target: $32.00 ▲(1.59%Upside)

Artivion's overall score is driven by strong technical momentum and positive earnings call guidance, highlighting growth potential. However, profitability challenges and valuation concerns temper the score.

Positive Factors

Growth Opportunities

The company's bets on the aortic arch repair space, including acquisitions and distribution options, are on the verge of paying off, indicating potential growth.

Operational Recovery

Despite the cybersecurity attack, Artivion is now operating near full capacity and expects significant revenue growth in the year.

Product Approval

The earlier-than-expected approval of the AMDS humanitarian-device-exemption is anticipated to positively contribute to 2025 top-line growth.

Negative Factors

Cybersecurity Impact

The December cybersecurity breach led to lower-than-expected 4Q24 sales, impacting the company's financial performance.

Financial Projections

The price target was lowered to $32 from $34, given the cybersecurity issue.

Revenue Challenges

Q1 is expected to continue feeling the impact of the cybersecurity incident, affecting revenue recognition.

Artivion Business Overview & Revenue Model

Company Description

Artivion, Inc. (AORT) is a medical device company that specializes in developing, manufacturing, and distributing innovative technologies for cardiac and vascular surgery. The company operates primarily in the healthcare sector, focusing on life-saving medical solutions for patients with aortic diseases. Artivion's core products include surgical sealants, cryopreserved cardiac and vascular tissues, and mechanical heart valves, which are used by surgeons and healthcare providers worldwide.

How the Company Makes Money

Artivion generates revenue through the sale of its medical devices and products to hospitals, healthcare facilities, and medical practitioners. The company's key revenue streams include the sale of surgical sealants, which are used to control bleeding during surgeries, and cryopreserved human tissues for cardiac and vascular reconstruction. Additionally, Artivion earns income through its mechanical heart valve products, which are crucial for patients requiring heart valve replacement. The company may also benefit from partnerships with healthcare providers and institutions that facilitate the adoption of its technologies in clinical settings. Sales and distribution agreements with global medical device distributors further expand its market reach, contributing to its financial performance.

Artivion Financial Statement Overview

Summary

Artivion demonstrates steady revenue growth with a solid gross profit margin. However, persistent net losses and negative net profit margins highlight profitability challenges. The balance sheet is stable with limited leverage, but high capital expenditures constrain free cash flow growth.

Income Statement

Artivion's income statement shows a modest revenue growth trend over the years, with TTM (Trailing-Twelve-Months) revenue at $390 million, representing a steady increase from previous years. However, the company has been consistently generating net losses, with a TTM net income of -$21.4 million. Gross profit margin remains strong at 62.9% TTM, but the negative net profit margin of -5.5% and declining EBIT margin to 4.5% TTM indicate profitability challenges.

Balance Sheet

The balance sheet reflects a stable equity base with stockholders' equity at $294 million TTM, but a high debt-to-equity ratio of 0.03 in TTM suggests manageable leverage. The equity ratio is a solid 37.2%, indicating a balanced capital structure. Despite these strengths, the negative net income affects return on equity, which remains negative.

Cash Flow

Artivion's cash flow statement indicates a mixed performance. While operating cash flow is positive at $13.6 million TTM, free cash flow growth is weak due to high capital expenditures, resulting in a modest free cash flow of $2.1 million TTM. The operating cash flow to net income ratio is positive, showing some operational efficiency despite net losses.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	388.54M	354.00M	313.79M	298.84M	253.23M
Gross Profit	248.78M	229.18M	202.52M	197.51M	167.78M
EBITDA	38.87M	26.87M	25.30M	25.67M	27.50M
Net Income	-13.36M	-30.69M	-19.19M	-14.83M	-16.68M
Balance Sheet
Total Assets	789.10M	792.40M	762.80M	793.05M	789.40M
Cash, Cash Equivalents and Short-Term Investments	53.46M	58.94M	39.35M	55.01M	61.41M
Total Debt	362.26M	358.34M	356.83M	362.04M	317.37M
Total Liabilities	512.90M	510.62M	478.47M	492.32M	460.69M
Stockholders Equity	276.20M	281.78M	284.33M	300.73M	328.71M
Cash Flow
Free Cash Flow	11.05M	11.39M	-15.87M	-15.68M	5.04M
Operating Cash Flow	22.24M	18.82M	-5.15M	-2.58M	12.37M
Investing Cash Flow	-28.19M	-502.00K	-10.71M	5.66M	-73.13M
Financing Cash Flow	2.20M	865.00K	-1.64M	-12.22M	93.61M

Artivion Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 31.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AORT, the sentiment is Positive. The current price of 31.5 is above the 20-day moving average (MA) of 31.11, above the 50-day MA of 30.09, and above the 200-day MA of 27.90, indicating a bullish trend. The MACD of 0.34 indicates Positive momentum. The RSI at 55.79 is Neutral, neither overbought nor oversold. The STOCH value of 58.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AORT.

Artivion Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KIDS	69 Neutral	$554.58M	―	-11.33%	―	31.28%	-81.86%
AORT	68 Neutral	$1.34B	―	-7.25%	―	5.94%	-115.82%
AXGN	63 Neutral	$591.62M	―	-7.22%	―	18.81%	67.41%
Sector *	57 Neutral	£4.92B	8.32	-62.36%	2.24%	34.00%	6.32%
OFIX	51 Neutral	$446.66M	―	-27.82%	―	5.85%	-8.92%
TNDM	48 Neutral	$1.12B	―	-92.31%	―	27.65%	-28.22%
BVS	47 Neutral	$536.40M	―	-19.79%	―	8.60%	-42.76%

Artivion Corporate Events

Artivion Completes Convertible Notes Exchange Agreement

On May 28, 2025, Artivion, Inc. announced the completion of transactions related to privately negotiated exchange agreements with holders of its 4.250% Convertible Senior Notes due 2025. These transactions involved exchanging approximately $99.54 million in principal amount of notes for 4,334,347 shares of common stock and a cash payment of $1.7 million for accrued interest. This move effectively retires the convertible notes, significantly reducing the company’s debt and enhancing its financial flexibility, as stated by CEO Pat Mackin.

The most recent analyst rating on (AORT) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Artivion stock, see the AORT Stock Forecast page.

Artivion Shareholders Approve Directors and Compensation

At the 2025 Annual Meeting of Stockholders on May 13, Artivion‘s shareholders elected all nominated directors and approved executive compensation packages. Additionally, they ratified Ernst & Young LLP as the independent auditor for 2025 and approved additional shares for the company’s equity incentive plan, indicating strong shareholder support for the company’s strategic direction.

The most recent analyst rating on (AORT) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Artivion stock, see the AORT Stock Forecast page.

Artivion Announces Convertible Notes Exchange Agreement

On May 14, 2025, Artivion, Inc. announced that it entered into privately negotiated exchange agreements with holders of its 4.250% Convertible Senior Notes due July 1, 2025. The agreements involve exchanging approximately $94.54 million in principal amount of these notes for shares of the company’s common stock, with the number of shares determined by the stock’s average trading price over a specified period. The transaction is expected to close around May 28, 2025, and will leave approximately $5.46 million of the notes outstanding. This strategic move is anticipated to impact Artivion’s financial structure and market positioning, potentially affecting stakeholders by altering the company’s debt and equity composition.

The most recent analyst rating on (AORT) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Artivion stock, see the AORT Stock Forecast page.